HK1203492A1 - 2 - (pyridin- 2yl) - 1, 7 -diaza- spiro [4.4]nonane- 6 -one compounds as voltage - gated sodium channels modulators - Google Patents
2 - (pyridin- 2yl) - 1, 7 -diaza- spiro [4.4]nonane- 6 -one compounds as voltage - gated sodium channels modulators Download PDFInfo
- Publication number
- HK1203492A1 HK1203492A1 HK15103930.0A HK15103930A HK1203492A1 HK 1203492 A1 HK1203492 A1 HK 1203492A1 HK 15103930 A HK15103930 A HK 15103930A HK 1203492 A1 HK1203492 A1 HK 1203492A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- voltage
- spiro
- diaza
- nonane
- pyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579613P | 2011-12-22 | 2011-12-22 | |
| GBGB1122113.2A GB201122113D0 (en) | 2011-12-22 | 2011-12-22 | Novel compounds |
| US201161579613P | 2011-12-22 | ||
| GB201122113 | 2011-12-22 | ||
| PCT/GB2012/053234 WO2013093497A1 (en) | 2011-12-22 | 2012-12-21 | 2 - (pyridin- 2yl) - 1, 7 -diaza- spiro [4.4] nonane- 6 -one compounds as voltage - gated sodium channels modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1203492A1 true HK1203492A1 (en) | 2015-10-30 |
Family
ID=45572877
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15103930.0A HK1203492A1 (en) | 2011-12-22 | 2012-12-21 | 2 - (pyridin- 2yl) - 1, 7 -diaza- spiro [4.4]nonane- 6 -one compounds as voltage - gated sodium channels modulators |
| HK15104075.3A HK1203501A1 (en) | 2011-12-22 | 2012-12-21 | 2 - (pyridin- 2yl) - 1, 7 -diaza-spiro [4.4]nonane- 6 -one compound as voltage-gated sodium channels modulator |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15104075.3A HK1203501A1 (en) | 2011-12-22 | 2012-12-21 | 2 - (pyridin- 2yl) - 1, 7 -diaza-spiro [4.4]nonane- 6 -one compound as voltage-gated sodium channels modulator |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9376436B2 (cs) |
| EP (2) | EP2794612B1 (cs) |
| JP (2) | JP2015502395A (cs) |
| KR (1) | KR20140113692A (cs) |
| CN (1) | CN104271581B (cs) |
| AU (1) | AU2012356386A1 (cs) |
| BR (1) | BR112014014940A2 (cs) |
| CA (1) | CA2858938C (cs) |
| EA (1) | EA026500B1 (cs) |
| ES (1) | ES2581327T3 (cs) |
| GB (1) | GB201122113D0 (cs) |
| HK (2) | HK1203492A1 (cs) |
| IL (1) | IL233215A0 (cs) |
| IN (1) | IN2014MN01469A (cs) |
| MX (1) | MX2014007637A (cs) |
| SG (1) | SG11201403356YA (cs) |
| WO (2) | WO2013093496A1 (cs) |
| ZA (1) | ZA201404269B (cs) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201122113D0 (en) * | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) * | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| RU2650523C1 (ru) | 2017-07-24 | 2018-04-16 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Производное пиридоксина для лечения эпилепсии |
| US11149039B2 (en) | 2017-10-10 | 2021-10-19 | Biogen Inc. | Process for preparing spiro derivatives |
| BR112020009361A2 (pt) | 2017-11-17 | 2020-10-13 | Cellix Bio Private Limited | composto de fórmula i, composição farmacêutica para tratar um distúrbio ocular ou complicações do mesmo, método de síntese de composto, método de tratamento de um distúrbio ocular ou complicações do mesmo em um indivíduo que precisa do mesmo e uso de um composto |
| CN113563258A (zh) * | 2021-07-29 | 2021-10-29 | 派普医药(江苏)有限公司 | 一种4-溴-2-(二氟甲基)-5-甲基吡啶的制备方法 |
| WO2023044364A1 (en) | 2021-09-15 | 2023-03-23 | Enko Chem, Inc. | Protoporphyrinogen oxidase inhibitors |
| MX2024003646A (es) * | 2021-09-24 | 2024-05-28 | Xenon Pharmaceuticals Inc | Derivados de piridinilo como activadores del canal de sodio. |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| WO1996025405A1 (en) | 1995-02-13 | 1996-08-22 | G.D. Searle & Co. | Substituted isoxazoles for the treatment of inflammation |
| UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
| SI22713B (sl) | 1996-04-12 | 2009-12-31 | Searle & Co | Substituirani benzensulfonamidni derivati kot predzdravila COX-2 inhibitorjev |
| EA001444B1 (ru) | 1996-07-18 | 2001-04-23 | Мерк Фросст Кэнада Энд Ко./Мерк Фросст Кэнада Э Си | Замещенные пиридины в качестве избирательных ингибиторов циклооксигеназы-2 |
| CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
| ATE317845T1 (de) | 1997-09-05 | 2006-03-15 | Glaxo Group Ltd | Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate |
| AU767464B2 (en) | 1998-11-03 | 2003-11-13 | Glaxo Group Limited | Pyrazolopyridine derivatives as selective COX-2 inhibitors |
| US6025683A (en) | 1998-12-23 | 2000-02-15 | Stryker Corporation | Motor control circuit for regulating a D.C. motor |
| ATE261444T1 (de) | 1999-02-27 | 2004-03-15 | Glaxo Group Ltd | Pyrazolopyridine |
| GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
| GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
| GB0323204D0 (en) | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
| SE0302811D0 (sv) * | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| GB0520578D0 (en) * | 2005-10-10 | 2005-11-16 | Glaxo Group Ltd | Novel compounds |
| ATE472529T1 (de) | 2005-10-10 | 2010-07-15 | Glaxo Group Ltd | Prolinamidderivate als natriumkanalmodulatoren |
| US8143306B2 (en) | 2005-10-10 | 2012-03-27 | Convergence Pharmaceuticals Limited | Methods of treating bipolar disorders |
| US7505330B2 (en) * | 2006-08-31 | 2009-03-17 | Micron Technology, Inc. | Phase-change random access memory employing read before write for resistance stabilization |
| GB0701366D0 (en) * | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0701365D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| JP2010516731A (ja) | 2007-01-24 | 2010-05-20 | グラクソ グループ リミテッド | ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物 |
| GB0706630D0 (en) | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
| WO2011029762A1 (en) | 2009-09-14 | 2011-03-17 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide derivatives |
| PE20170202A1 (es) * | 2009-10-14 | 2017-03-24 | Xenon Pharmaceuticals Inc | Metodos sinteticos para compuestos espiro-oxoindol |
| GB201122113D0 (en) * | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
-
2011
- 2011-12-22 GB GBGB1122113.2A patent/GB201122113D0/en not_active Ceased
-
2012
- 2012-12-21 JP JP2014548202A patent/JP2015502395A/ja active Pending
- 2012-12-21 EA EA201491251A patent/EA026500B1/ru unknown
- 2012-12-21 CA CA2858938A patent/CA2858938C/en active Active
- 2012-12-21 CN CN201280070485.0A patent/CN104271581B/zh not_active Expired - Fee Related
- 2012-12-21 WO PCT/GB2012/053233 patent/WO2013093496A1/en not_active Ceased
- 2012-12-21 HK HK15103930.0A patent/HK1203492A1/xx unknown
- 2012-12-21 HK HK15104075.3A patent/HK1203501A1/xx unknown
- 2012-12-21 MX MX2014007637A patent/MX2014007637A/es unknown
- 2012-12-21 WO PCT/GB2012/053234 patent/WO2013093497A1/en not_active Ceased
- 2012-12-21 AU AU2012356386A patent/AU2012356386A1/en not_active Abandoned
- 2012-12-21 KR KR1020147019965A patent/KR20140113692A/ko not_active Withdrawn
- 2012-12-21 ES ES12810416.3T patent/ES2581327T3/es active Active
- 2012-12-21 SG SG11201403356YA patent/SG11201403356YA/en unknown
- 2012-12-21 BR BR112014014940A patent/BR112014014940A2/pt not_active Application Discontinuation
- 2012-12-21 EP EP12810417.1A patent/EP2794612B1/en not_active Not-in-force
- 2012-12-21 JP JP2014548201A patent/JP2015502394A/ja active Pending
- 2012-12-21 US US14/365,372 patent/US9376436B2/en not_active Expired - Fee Related
- 2012-12-21 EP EP12810416.3A patent/EP2797922B1/en not_active Not-in-force
- 2012-12-21 IN IN1469MUN2014 patent/IN2014MN01469A/en unknown
- 2012-12-21 US US14/365,391 patent/US9303032B2/en not_active Expired - Fee Related
-
2014
- 2014-06-10 ZA ZA2014/04269A patent/ZA201404269B/en unknown
- 2014-06-18 IL IL233215A patent/IL233215A0/en unknown
-
2016
- 2016-02-25 US US15/053,445 patent/US20160185758A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN104271581A (zh) | 2015-01-07 |
| EP2797922A1 (en) | 2014-11-05 |
| MX2014007637A (es) | 2014-09-26 |
| US9303032B2 (en) | 2016-04-05 |
| US20160185758A1 (en) | 2016-06-30 |
| IL233215A0 (en) | 2014-08-31 |
| US20150225400A1 (en) | 2015-08-13 |
| WO2013093496A1 (en) | 2013-06-27 |
| GB201122113D0 (en) | 2012-02-01 |
| AU2012356386A1 (en) | 2014-07-10 |
| ES2581327T3 (es) | 2016-09-05 |
| CA2858938C (en) | 2020-03-10 |
| SG11201403356YA (en) | 2014-07-30 |
| EP2794612A1 (en) | 2014-10-29 |
| HK1203501A1 (en) | 2015-10-30 |
| CN104271581B (zh) | 2016-08-31 |
| EA026500B1 (ru) | 2017-04-28 |
| JP2015502395A (ja) | 2015-01-22 |
| EP2797922B1 (en) | 2016-04-06 |
| WO2013093497A1 (en) | 2013-06-27 |
| BR112014014940A2 (pt) | 2017-06-13 |
| US20140350040A1 (en) | 2014-11-27 |
| CA2858938A1 (en) | 2013-06-27 |
| EA201491251A1 (ru) | 2014-11-28 |
| EP2794612B1 (en) | 2016-04-06 |
| IN2014MN01469A (cs) | 2015-04-17 |
| JP2015502394A (ja) | 2015-01-22 |
| KR20140113692A (ko) | 2014-09-24 |
| US9376436B2 (en) | 2016-06-28 |
| ZA201404269B (en) | 2016-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1203492A1 (en) | 2 - (pyridin- 2yl) - 1, 7 -diaza- spiro [4.4]nonane- 6 -one compounds as voltage - gated sodium channels modulators | |
| WO2012155066A3 (en) | Spiro-oxindole mdm2 antagonists | |
| WO2012177844A3 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| MX347917B (es) | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. | |
| WO2012118812A3 (en) | Substituted 6,5-fused bicyclic heteroaryl compounds | |
| PH12013502240B1 (en) | Novel compounds as modulators of protein kinase | |
| GEP201706695B (en) | Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases | |
| WO2012065022A3 (en) | Spiro-oxindole mdm2 antagonists | |
| IN2014DN07384A (cs) | ||
| AU2012265219A8 (en) | Compounds containing hydrido-tricyano-borate anions | |
| WO2011082266A3 (en) | Substituted heterocyclic compounds | |
| NZ629499A (en) | Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases | |
| WO2011123678A3 (en) | Substituted benzo-pyrido-triazolo-diazepine compounds | |
| WO2012104823A3 (en) | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases | |
| HK1209105A1 (en) | Vegfr3 inhibitors | |
| WO2013007361A8 (en) | Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine | |
| WO2014026039A3 (en) | Aryl-and heteroaryl-substituted benzene derivatives as modulators of pi3-kinase signalling pathways | |
| HK1209104A1 (en) | Vegfr3 inhibitors | |
| PT2770979E (pt) | Composição de reticulação melhorada administrada por iontoforese, útil para o tratamento do queratocone | |
| GB201209015D0 (en) | Novel compounds | |
| WO2012061342A3 (en) | Substituted benzo-imidazo-pyrido-diazepine compounds | |
| WO2013163562A3 (en) | Compositions and methods for treating ptsd and related diseases | |
| WO2013048949A3 (en) | Selective nr2b antagonists | |
| WO2011082271A3 (en) | Substituted triazolo-pyrimidine compounds | |
| WO2010033451A3 (en) | 5-oxazolidin-2-one substituted 1,3,8-triazaspiro [4.5] decan-4-one derivatives useful as orl-1 receptor modulators |